-
1 Comment
Shenzhen Lifotronic Technology Co., Ltd is currently in a long term uptrend where the price is trading 18.7% above its 200 day moving average.
From a valuation standpoint, the stock is 40.2% more expensive than other stocks from the None sector with a price to sales ratio of 17.4.
Shenzhen Lifotronic Technology Co., Ltd's total revenue rose by 30.4% to $161M since the same quarter in the previous year.
Its net income has increased by 48.1% to $51M since the same quarter in the previous year.
Based on the above factors, Shenzhen Lifotronic Technology Co., Ltd gets an overall score of 3/5.
| ISIN | CNE100005WZ5 |
|---|---|
| Sector | Healthcare |
| Industry | Medical Devices |
| Exchange | SHG |
| CurrencyCode | CNY |
| PE Ratio | 16.91 |
|---|---|
| Target Price | 26.3 |
| Beta | 0.47 |
| Market Cap | 6B |
| Dividend Yield | None |
Shenzhen Lifotronic Technology Co., Ltd. research, develops, manufactures, and markets medical devices for diagnostics, clinical medicine, skin, and human health related purposes in China. The company offers IVD products, such as HPLC, ECLIA, and hematology system; rapid test, molecular and POCT diagnostics. It also offers therapeutic products comprising respiratory and ICU, and wound care; electromagnetic and pneumatic shockwave products. In addition, the company provides medical and aesthetic, and laser hair removal products, as well as offers E-training services. Further, it offers medical beauty related products. Shenzhen Lifotronic Technology Co., Ltd. was founded in 2008 and is headquartered in Shenzhen, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 688389.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
